	US 12,233,065 B2
	Inhibitors of RNA helicase DHX9 and uses thereof
Matthew H. Daniels, Somerville, MA (US); Kenneth W. Duncan, Westwood, MA (US); Brian Andrew Sparling, Saugus, MA (US); Andrew Stewart Tasker, Simi Valley, CA (US); and Gavin Whitlock, Lexington, MA (US)
Assigned to ACCENT THERAPEUTICS, INC., Lexington, MA (US)
Filed by ACCENT THERAPEUTICS, INC., Lexington, MA (US)
Filed on Mar. 28, 2024, as Appl. No. 18/620,110.
Application 18/620,110 is a continuation of application No. PCT/US2023/012929, filed on Feb. 13, 2023.
Claims priority of provisional application 63/309,917, filed on Feb. 14, 2022.
Prior Publication US 2024/0316047 A1, Sep. 26, 2024
Int. Cl. A61K 31/506 (2006.01); A61K 31/18 (2006.01); A61K 31/277 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/437 (2006.01); A61K 31/4418 (2006.01); A61K 31/4436 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61K 31/675 (2006.01); A61P 35/00 (2006.01); C07C 311/08 (2006.01); C07D 207/34 (2006.01); C07D 213/56 (2006.01); C07D 231/12 (2006.01); C07D 231/14 (2006.01); C07D 233/90 (2006.01); C07D 307/68 (2006.01); C07D 333/38 (2006.01); C07D 333/70 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 409/04 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07F 9/6558 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 31/18 (2013.01); A61K 31/277 (2013.01); A61K 31/341 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/437 (2013.01); A61K 31/4418 (2013.01); A61K 31/4436 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/4985 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61P 35/00 (2018.01); C07C 311/08 (2013.01); C07D 207/34 (2013.01); C07D 213/56 (2013.01); C07D 231/12 (2013.01); C07D 231/14 (2013.01); C07D 233/90 (2013.01); C07D 307/68 (2013.01); C07D 333/38 (2013.01); C07D 333/70 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 409/04 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07F 9/65583 (2013.01)]

16 Claims

1. A compound represented by Formula (IVB):

or a pharmaceutically acceptable salt thereof, wherein:

m is 1;

R¹is —CH₃;

X is Cl;

R²is —CH₃;

R³is pyrimidinyl or pyridinyl, each of which is optionally substituted with 1 or 2 R⁴;

R⁴is halo, —OC_1-3alkyl, or 4- to 6-membered monocyclic heterocyclyl, wherein the 4- to 6-membered monocyclic heterocyclyl is optionally substituted with 1 or 2 halo or C_1-3haloalkyl.